J Lab Med Qual Assur.  2018 Jun;40(2):70-76. 10.15263/jlmqa.2018.40.2.70.

Annual Report on the External Quality Assessment Scheme for Tumor Markers in Korea (2017)

Affiliations
  • 1Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. cloak21@snu.ac.kr

Abstract

In 2017, the tumor marker program of the Korean Association of External Quality Assessment Service was performed for tumor markers I and II. Tumor marker I comprised alpha-fetoprotein (AFP), carcinoembryonic antigen, protein induced by vitamin K absence-II, and prostate specific antigen (PSA), and tumor marker II comprised cancer antigen (CA) 125, CA 19-9, CA 15-3, CA 72-4, and beta-2-microglobulin. Two challenges were conducted with three pooled serum or control materials, except for the first tumor marker I challenge. In total, 648 institutions participated in tumor marker I and 380 in tumor marker II programs. The response rates were 92.9%-97.0%. The coefficients of variation (CVs) were different depending on tests and samples, and average CVs were 3.7%-16.8%. The average CV of CA 72-4 tests, whose number of participants was the smallest, was the lowest. The average CV of AFP tests, which included a sample with very high levels, was the highest.

Keyword

Proficiency testing; Tumor marker; Korean Association of External Quality Assessment Service

MeSH Terms

alpha-Fetoproteins
Biomarkers, Tumor*
Carcinoembryonic Antigen
Korea*
Prostate-Specific Antigen
Vitamin K
Biomarkers, Tumor
Carcinoembryonic Antigen
Prostate-Specific Antigen
Vitamin K
alpha-Fetoproteins
Full Text Links
  • JLMQA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error